{"id":3675,"date":"2016-03-14T17:17:03","date_gmt":"2016-03-14T15:17:03","guid":{"rendered":"http:\/\/backup.altanalaw.com\/?p=3675"},"modified":"2016-03-14T17:19:35","modified_gmt":"2016-03-14T15:19:35","slug":"altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics","status":"publish","type":"post","link":"https:\/\/backup.altanalaw.com\/ja\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics","title":{"rendered":"Altana conseille ONXEO dans l’acquisition de DNA Therapeutics"},"content":{"rendered":"

\u7533\u3057\u8a33\u3042\u308a\u307e\u305b\u3093\u3001\u3053\u306e\u30b3\u30f3\u30c6\u30f3\u30c4\u306f\u305f\u3060\u4eca\u3000Fran\u00e7ais<\/a>\u3068 English<\/a>\u3000\u306e\u307f\u3067\u3059\u3002 For the sake of viewer convenience, the content is shown below in this site default language. You may click one of the links to switch the site language to another available language.<\/p>

ALTANA conseille ONXEO, soci\u00e9t\u00e9 cot\u00e9e sur le compartiment B d\u2019Euronext Paris et sur le NASDAQ\u00a0Copenhague, dans le cadre de la conclusion d\u2019un accord engageant relatif \u00e0 l\u2019acquisition de DNA\u00a0Therapeutics.<\/strong><\/p>\n

DNA Therapeutics est une soci\u00e9t\u00e9 biopharmaceutique qui dispose d\u2019une nouvelle classe de\u00a0m\u00e9dicaments dans la lutte contre le cancer. Cette nouvelle acquisition permet \u00e0 ONXEO de diversifier\u00a0son portefeuille-produits et lui offre des perspectives sur de nouvelles indications orphelines en\u00a0oncologie.<\/p>\n

L\u2019acquisition de DNA Therapeutics d\u00e9montre une nouvelle fois l\u2019ambition d\u2019ONXEO d\u2019\u00eatre un leader\u00a0du d\u00e9veloppement de m\u00e9dicaments innovants dans les pathologies orphelines canc\u00e9reuses et\u00a0positionne la soci\u00e9t\u00e9 \u00e0 la pointe de la recherche m\u00e9dicale avec un potentiel de cr\u00e9ation de valeur\u00a0significatif pour ses actionnaires.<\/p>\n

Selon les modalit\u00e9s de l\u2019accord, ONXEO acquerra DNA Therapeutics pour un montant initial de\u00a0 1,7\u00a0million d\u2019Euros en actions ordinaires d\u2019ONXEO, qui seront vers\u00e9es concomitamment \u00e0 la\u00a0r\u00e9alisation de l\u2019op\u00e9ration. Une r\u00e9mun\u00e9ration additionnelle sera vers\u00e9e sous forme de paiement\u00a0d\u2019\u00e9tapes, \u00e0 savoir\u00a01 million d\u2019Euros en actions ONXEO, ou en num\u00e9raire \u00e0 la discr\u00e9tion d\u2019ONXEO,\u00a0lorsque le produit entrera en phase II dans une des indications s\u00e9lectionn\u00e9es. Enfin, il est pr\u00e9vu le\u00a0versement de royalties sur ventes en cas de commercialisation du produit, pour une valeur pouvant\u00a0atteindre 25 millions d\u2019Euros par indication th\u00e9rapeutique.<\/p>\n

ALTANA avait d\u00e9j\u00e0 conseill\u00e9 ONXEO (anciennement BIOALLIANCE PHARMA) dans le cadre de sa\u00a0fusion transfrontali\u00e8re avec la soci\u00e9t\u00e9 danoise TOPOTARGET en 2014. Il s\u2019agissait de la premi\u00e8re\u00a0fusion transfrontali\u00e8re entre une soci\u00e9t\u00e9 fran\u00e7aise cot\u00e9e et une soci\u00e9t\u00e9 cot\u00e9e de nationalit\u00e9\u00a0diff\u00e9rente, sous le r\u00e9gime de la Directive de 2005 sur les fusions.<\/p>\n

– Acqu\u00e9reur : ONXEO<\/strong><\/span><\/p>\n

– Conseils juridiques : ALTANA (Jean-Nicolas Soret \/ Fabien Pouchot)<\/p>\n

– Conseils fiscaux\u00a0: ARSENE TAXAND (Olivier Vergniolle \/ Marion Dervieux)<\/p>\n

– Conseils financiers : ERNST & YOUNG (J\u00e9r\u00f4me Vailland \/ Mehdi Houkari)<\/p>\n

– Vendeur :\u00a0Titulaires de titres DNA Therapeutics<\/span><\/strong><\/p>\n

– Conseils juridiques : HBC Avocats (Erwan COSS\u00c9 \/ Laurent COMPEROT)<\/p>","protected":false},"excerpt":{"rendered":"

\u7533\u3057\u8a33\u3042\u308a\u307e\u305b\u3093\u3001\u3053\u306e\u30b3\u30f3\u30c6\u30f3\u30c4\u306f\u305f\u3060\u4eca\u3000Fran\u00e7ais<\/a>\u3068 English<\/a>\u3000\u306e\u307f\u3067\u3059\u3002 For the sake of viewer convenience, the content is shown below in this site default language. You may click one of the links to switch the site language to another available language.<\/p>\n

ALTANA conseille ONXEO, soci\u00e9t\u00e9 cot\u00e9e sur le compartiment B d\u2019Euronext Paris et sur le NASDAQ Copenhague, dans le cadre de la conclusion d\u2019un accord engageant relatif \u00e0 l\u2019acquisition de DNA Therapeutics.<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3675","post","type-post","status-publish","format-standard","hentry","category-medias","expertise-droit-societes-fusions-acquisitions"],"yoast_head":"\n<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"[:fr]Altana conseille ONXEO dans l'acquisition de DNA Therapeutics[:en]Altana advises ONXEO in the acquisition of DNA Therapeutics[:] - Altana\" \/>\n<meta property=\"og:description\" content=\"[:fr]ALTANA conseille ONXEO, soci\u00e9t\u00e9 cot\u00e9e sur le compartiment B d\u2019Euronext Paris et sur le NASDAQ Copenhague, dans le cadre de la conclusion d\u2019un accord engageant relatif \u00e0 l\u2019acquisition de DNA Therapeutics.[:en]Altana advises ONXEO, a company listed on Compartment B of Euronext Paris and on the Copenhagen NASDAQ, in the execution of a binding agreement to acquire DNA Therapeutics. [:]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics\" \/>\n<meta property=\"og:site_name\" content=\"Altana\" \/>\n<meta property=\"article:published_time\" content=\"2016-03-14T15:17:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2016-03-14T15:19:35+00:00\" \/>\n<meta name=\"author\" content=\"Altana Communication\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Altana Communication\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics\",\"url\":\"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics\",\"name\":\"[:fr]Altana conseille ONXEO dans l'acquisition de DNA Therapeutics[:en]Altana advises ONXEO in the acquisition of DNA Therapeutics[:] - Altana\",\"isPartOf\":{\"@id\":\"https:\/\/backup.altanalaw.com\/#website\"},\"datePublished\":\"2016-03-14T15:17:03+00:00\",\"dateModified\":\"2016-03-14T15:19:35+00:00\",\"author\":{\"@id\":\"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/backup.altanalaw.com\/#website\",\"url\":\"https:\/\/backup.altanalaw.com\/\",\"name\":\"Altana\",\"description\":\"Soci\u00e9t\u00e9 d'avocats \u00e0 la Cour de Paris\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/backup.altanalaw.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ja\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6\",\"name\":\"Altana Communication\",\"url\":\"https:\/\/backup.altanalaw.com\/ja\/author\/altanacomm\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"[:fr]Altana conseille ONXEO dans l'acquisition de DNA Therapeutics[:en]Altana advises ONXEO in the acquisition of DNA Therapeutics[:] - Altana","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"ja_JP","og_type":"article","og_title":"[:fr]Altana conseille ONXEO dans l'acquisition de DNA Therapeutics[:en]Altana advises ONXEO in the acquisition of DNA Therapeutics[:] - Altana","og_description":"[:fr]ALTANA conseille ONXEO, soci\u00e9t\u00e9 cot\u00e9e sur le compartiment B d\u2019Euronext Paris et sur le NASDAQ Copenhague, dans le cadre de la conclusion d\u2019un accord engageant relatif \u00e0 l\u2019acquisition de DNA Therapeutics.[:en]Altana advises ONXEO, a company listed on Compartment B of Euronext Paris and on the Copenhagen NASDAQ, in the execution of a binding agreement to acquire DNA Therapeutics. [:]","og_url":"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics","og_site_name":"Altana","article_published_time":"2016-03-14T15:17:03+00:00","article_modified_time":"2016-03-14T15:19:35+00:00","author":"Altana Communication","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"Altana Communication","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"3\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics","url":"https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics","name":"[:fr]Altana conseille ONXEO dans l'acquisition de DNA Therapeutics[:en]Altana advises ONXEO in the acquisition of DNA Therapeutics[:] - Altana","isPartOf":{"@id":"https:\/\/backup.altanalaw.com\/#website"},"datePublished":"2016-03-14T15:17:03+00:00","dateModified":"2016-03-14T15:19:35+00:00","author":{"@id":"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/backup.altanalaw.com\/medias\/altana-conseille-onxeo-dans-lacquisition-de-dna-therapeutics"]}]},{"@type":"WebSite","@id":"https:\/\/backup.altanalaw.com\/#website","url":"https:\/\/backup.altanalaw.com\/","name":"Altana","description":"Soci\u00e9t\u00e9 d'avocats \u00e0 la Cour de Paris","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/backup.altanalaw.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ja"},{"@type":"Person","@id":"https:\/\/backup.altanalaw.com\/#\/schema\/person\/4bdb47072f79b38f30b44735a4377af6","name":"Altana Communication","url":"https:\/\/backup.altanalaw.com\/ja\/author\/altanacomm"}]}},"_links":{"self":[{"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/posts\/3675"}],"collection":[{"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/comments?post=3675"}],"version-history":[{"count":2,"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/posts\/3675\/revisions"}],"predecessor-version":[{"id":3678,"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/posts\/3675\/revisions\/3678"}],"wp:attachment":[{"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/media?parent=3675"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/categories?post=3675"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/backup.altanalaw.com\/ja\/wp-json\/wp\/v2\/tags?post=3675"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}